Safety study of a glioblastoma device for recurring tumors
Part of Cancer clinical trials.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and agree to sign the consent form
- Your expected survival is at least 12 weeks, and you can follow all study visits
- You have confirmed glioblastoma that has come back or grown on MRI and is measurable
- You have had surgery plus radiation and chemotherapy before, with enough time since those treatments
- You must have good blood counts and overall organ health from recent lab tests
- Your brain blood-vessel anatomy must allow a catheter to be safely placed for the planned treatment spots
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to deliver radiation directly to the tumor using tiny beads placed during a procedure. It is for people whose glioblastoma has come back after standard treatments, and it aims to slow or stop tumor growth.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a treatment that delivers tiny radioactive beads directly to the blood vessels feeding a recurrent brain tumor, aiming to kill cancer cells while sparing healthy tissue. It is for people whose glioblastoma has returned after standard treatments like radiation and chemotherapy.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.